Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Non Operating Income (2016 - 2026)

Sunshine Biopharma filings provide 12 years of Non Operating Income readings, the most recent being $57458.0 for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 106.87% to $57458.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $273286.0, a 241.12% increase, with the full-year FY2025 number at $273286.0, up 289.16% from a year prior.
  • Non Operating Income hit $57458.0 in Q4 2025 for Sunshine Biopharma, down from $65355.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $946747.0 in Q4 2021 to a low of -$4.9 million in Q1 2021.
  • Median Non Operating Income over the past 5 years was $86870.0 (2022), compared with a mean of -$436419.1.
  • Biggest five-year swings in Non Operating Income: plummeted 8580.13% in 2021 and later surged 1442.82% in 2023.
  • Sunshine Biopharma's Non Operating Income stood at $946747.0 in 2021, then tumbled by 91.06% to $84599.0 in 2022, then skyrocketed by 86.13% to $157464.0 in 2023, then tumbled by 631.45% to -$836848.0 in 2024, then surged by 106.87% to $57458.0 in 2025.
  • The last three reported values for Non Operating Income were $57458.0 (Q4 2025), $65355.0 (Q3 2025), and $74655.0 (Q2 2025) per Business Quant data.